NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
IPO Year: 2021
Exchange: NASDAQ
Website: https://nexgel.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/25/2022 | $6.00 | Buy | Maxim Group |
10-Q - NEXGEL, INC. (0001468929) (Filer)
NT 10-Q - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
424B5 - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
10-K/A - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatmentsSeveral states have already either instituted or are considering surgical plume protection mandates as a requirement to contain the toxic byproduct of laser proceduresLANGHORNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, and Innovative Optics US dba Vanalay, a leading supplier of safety products and personal prote
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Helen of Troy Limited (NASDAQ:HELE) to report quarterly earnings at $1.59 per share on revenue of $445.86 million before the opening bell, according to data from Benzinga Pro. Helen of Troy shares gained 0.3% to $89.30 in the after-hours trading session. NEXGEL, Inc. (NASDAQ:NXGL) issued preliminary revenue guidance above estimates. The company said it sees third-quarter revenue of $2.2 million versus estimates of $2.091 million. It expects fourth-quarter revenue of $2.6 million versus expectations of $2.467 million. NexGel shares ju
Adam Levy, CEO of NEXGEL, commented, "We are pleased to deliver record revenue for the second quarter of 2024 in spite of lower-than-normal revenues at CG Converting and Packaging due to our move into our newly expanded facility. We are also pleased to provide an outlook for our expected results for the second half of this year that has exceeded our expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is primarily due to new customer relationships with large global corporations. Additionally, many of our brands are also experiencing significant growth. Silly George is leading the way with strong consumer demand for our new Pop-On Lash produ
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will supply SilverSeal to Cintas Corporation, a leading provider of corporate identity uniforms, first aid and safety products, and services to over 1 million businesses across North America. Through this supply arrangement, Cintas will distribute SilverSeal to its customers in many sectors such as hospitality and public service. SilverSeal, a hospital-grade hydrogel dressing for wounds and burns will be offered as a wound care solution for employees of their
NEXGEL has acquired all of the assets of Silly George for $400,000 in cash, $200,000 in NEXGEL common stock, and a 4-year net profit earn out. Under the terms of the agreement, management of Silly George will remain in place and inventory will be provided by the seller at cost and paid for after the sale of each unit.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2024 Financial Results Conference CallDate: August 14, 2024Time: 4:30 P.M. ETLive Call: + 1-8
Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George, an international beauty company with specialty in eye and eyelash consumer products and a revenue run rate of approximately $2 million. Silly George offers its loyal consumer base a full product line of eye and eyelash products including hassle-free alte
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2024, after the market closes on May 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. First Quarter 2024 Financial Results Conference CallDate: May 13, 2024Time: 4:30 P.M. ETLive Call: + 1-800-343-54
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced rescheduling its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET. The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call. Adam Levy, CEO of NEXGEL, commented, "In light of the stock markets being closed to observe the Good Friday holiday, we are moving the reporting of our 2023 financial
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market closes on March 28, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2023 Financial Results Conference Call Date:
Acquisition expands NEXGEL's health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins Kenkoderm for the trailing twelve months is profitable and expected to be immediately accretive to NEXGEL LANGHORNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Kenkoderm, a privately-owned skincare product company focusing on treating the symptoms of Psoriasis, effective December 1, 2023. The Kenkoderm s
Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the third quarter ended September 30, 2023. Adam Levy, NEXGEL's Chief Executive Officer, commented, "We are pleased to deliver yet another record revenue quarter of $1.2 million, an increase of 115% year-over-year, driven by growth year-over-year in both contract manufacturing and branded consumer products. Importantly, gross margins during the
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter ended September 30, 2023, after the market closes on November 13, 2023. Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on November 13, 2023. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portio
LANGHORNE, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced financial results for the second quarter ended June 30, 2023. Adam Levy, NEXGEL's Chief Executive Officer, commented, "Record second quarter revenue of $1.17 million, an increase of 108% year-over-year, exceeded our projections. Our contract manufacturing line of business increased 174% year-over-year, predominately due to the full quarter contribution of our joint venture with C.G. Laboratories as well as increased demand from our existing contract cus
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 02, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter ended June 30, 2023, after the market closes on August 14, 2023. Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on August 14, 2023. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively. Adam Levy, NEXGEL's Chief Executive Officer, commented, "The second quarter of 2024 was a record revenue quarter for the Company, totaling $1.44 million, an increase of 23.4% year-over-year and 13.7% sequentially. Branded consumer product revenue was a key growth driver during the q
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2024 Financial Results Conference CallDate: August 14, 2024Time: 4:30 P.M. ETLive Call: + 1-8
LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 444,000 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 222,000 shares of common stock for a combined offering purchase price of $2.50 per share of common stock in a registered direct offering priced. The warrants will have an exercise price of $4.25 per share and be exercisable imm
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments Several states have already either instituted or are considering surgical plume protection mandates as a requirement to contain the toxic byproduct of laser procedures LANGHORNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, and Innovative Optics US dba Vanalay, a leading supplier of safety products and personal
LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024. Based on preliminary and unaudited review, the Company anticipates: Second Quarter 2024 Revenue: $1.4 million, an increase of approximately 20% year-over-year and 10% sequentiallyThird Quarter 2024 Revenue: $2.2 million, an increase of 83% year-over-yearFourth Quarter 2024 R
LANGHORNE, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will supply SilverSeal to Cintas Corporation, a leading provider of corporate identity uniforms, first aid and safety products, and services to over 1 million businesses across North America. Through this supply arrangement, Cintas will distribute SilverSeal to its customers in many sectors such as hospitality and public service. SilverSeal, a hospital-grade hydrogel dressing for wounds and burns will be o
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG ("STADA"), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin
Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George, an international beauty company with specialty in eye and eyelash consumer products and a revenue run rate of approximately $2 million. Silly George offers its loyal consumer base a full product line of eye and eyelash products including hassle-free alte
LANGHORNE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the first quarter ended March 31, 2024. Adam Levy, NEXGEL's Chief Executive Officer, commented, "Following a record year of growth in 2023, I am pleased to report our first quarter financial results that demonstrate steady growth year-over-year and preparedness for significant growth levers we expect in 2024. Revenue for the quarter grew 104% year-over-year driven by growth in both contract manufacturing and consumer branded pro
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2024, after the market closes on May 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. First Quarter 2024 Financial Results Conference CallDate: May 13, 2024Time: 4:30 P.M. ETLive Call: + 1-800-343-54
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL, NXGLW))), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson serves as Co-Director of the pediatric ophthalmology department and Director of the Strabismus Center at Wills Eye Hospital. He is an associate professor of ophthalmology and pediatrics at Thomas Jefferson University's Sidney Kimmel Medical College and staff member at Thomas Jefferson University Hospital, Lankenau Medical Center and
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)